Mira stood in the back of the auditorium. She had changed: where once she collected samples, now she collected lost things—a chipped teacup left in a park, a scrap of sheet music scrawled in an abandoned piano. She had begun to see the pattern of the vial like a gardener sees the rhythm of rain; it wasn't simply distributing memories. It was offering new beginnings, small improvisations on the rules of remembering.
The mechanism of action of HMN-384 is distinct from current standards of care. By inhibiting CDK11, HMN-384 disrupts the transcription-splicing axis, a vulnerability particularly pronounced in the "transcriptionally addicted" TNBC subtype. The induction of intron retention suggests that cancer cells cannot tolerate the loss of CDK11-mediated RNA processing, leading to apoptotic cell death. This mechanism provides a rationale for the use of HMN-384 in tumors that have developed resistance to CDK4/6 inhibitors via Rb loss or Cyclin E amplification. HMN-384